Alk-Abello As B Shs New (AKBLF) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Alk-abello A/s Class B.

Watch the replay

Replay transcript excerpt

WEBVTT NOTE Transcription provided by Deepgram Request Id: 01a040d7-609b-70f3-8199-d89646a748fe Created: 2026-08-27T01:30:56.663Z Duration: 3421.44 Channels: 1 00:00:00.000 -- 00:00:02.399 Hello, everyone, and welcome to this presentation of 00:00:02.399 -- 00:00:05.279 ALK's Q2 and First Half Year Results. Thank 00:00:05.279 -- 00:00:07.359 you all for joining us. Let's turn to 00:00:07.359 -- 00:00:09.360 Slide number two with an introduction to the 00:00:09.360 -- 00:00:10.879 speakers and the agenda. 00:00:11.519 -- 00:00:13.280 My name is Piotr Plotnikov, I'm Head of 00:00:13.280 -- 00:00:16.235 Investor Relations. With me today are CEO, Peter 00:00:16.235 -- 00:00:19.035 Helling and CFO, Clout Steinsensoglen. 00:00:19.195 -- 00:00:20.875 Peter and Clout will walk you through the 00:00:20.875 -- 00:00:24.074 quarterly highlights, markets, product trends and financials. 00:00:24.474 -- 00:00:26.474 After a brief strategy update, we will turn 00:00:26.474 -- 00:00:28.490 to the full year outlook. And as usual, 00:00:28.490 -- 00:00:29.690 we will end the call with a Q 00:00:29.690 -- 00:00:30.570 and A session. 00:00:30.730 -- 00:00:32.409 First, I'll hand you over to Peter to 00:00:32.409 -- 00:00:34.330 the highlights on Slide three. Please go ahead, 00:00:34.330 -- 00:00:34.890 Peter. 00:00:35.210 -- 00:00:37.610 Thank you, Peer, and thank you all for 00:00:37.610 -- 00:00:39.530 taking the time to listen to this call. 00:00:40.250 -- 00:00:42.970 Alk sustained strong sales momentum in Q2, 00:00:43.565 -- 00:00:46.524 with double digit sales growth across all regions, 00:00:46.684 -- 00:00:49.805 driven mainly by tablets and anaphylaxis products. 00:00:50.765 -- 00:00:53.565 Revenue grew by 18% in local currencies to 00:00:53.565 -- 00:00:55.565 close to 1,800,...